| UHC Commercial Medical & Drug | Category III Codes – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Cell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Chelation Therapy – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Cognitive Rehabilitation and Coma Stimulation – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Gender Dysphoria Treatment – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Genetic Testing for Hereditary Cancer – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Home Health, Skilled, and Custodial Care Services – Commercial and Individual Exchange Medical Policy | 2026-07-01 |